Nectar Lifesciences Share Price

Nectar Lifesciences Investment Rating

• Master Rating:

• Nectar Lifesciences has an operating revenue of Rs. 1,710.90 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 2% needs improvement, ROE of 2% is fair but needs improvement. The company has a reasonable debt to equity of 27%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 27 which is a POOR score indicating inconsistency in earnings, a RS Rating of 17 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 112 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of E is the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.